Dr. Keefer has over 18 years of experience in the preventive HIV vaccine field, having served as Director of the University of Rochester's NIH-supported HIV Vaccine Trials Unit (HVTU) since 1991. Working initially as a laboratory investigator he was the first to demonstrate T-cell mediated immune responses to a candidate HIV vaccine. Subsequently he focused his attention on the design and conduct of clinical trials. When the HIV Vaccine Trials Network (HVTN) expanded to include international sites in 1999, he assumed the position of the HVTN's Associate Director of Scientific Administration. In that role his duties include leadership of scientific and administrative committees and visits to international sites. Dr Keefer is also PI of an NIH-funded Program Project entitled "HSV-1 amplicon vectors for HIV vaccine delivery", a collaboration with Drs. Dewhurst, Mosmann, Federoff and Bowers.
2/1/2007 – 11/30/2014
PI: Richard C. Reichman, MD
"Units for HIV/AIDS Clinical Trials Networks"
The goals of the of the CTU are to develop a vaccine that will prevent HIV infection or delay the onset of symptomatic disease (HVTN) and to develop more effective treatments for established HIV infection in a variety of patient populations (ACTG).
Role: Co-Investigator, Director of HIV Vaccine Trials Clinical Research Site
6/29/2006 – 5/31/2013
PI: L Corey, M.D.
Subcontract to University of Rochester (via Fred Hutchinson Cancer Research Center, Seattle, WA)
Title: "HVTN Associate Director of Scientific Administration",
The major goal is to establish a Vaccine Leadership Group to direct and coordinate the HIV Vaccine Trials Network's (HVTN) work in domestic and international settings. Dr. Keefer functions in a 40% FTE capacity as a key member of the network's Core Operations Center, focused primarily on the establishment and execution of the network's scientific agenda for Phase I/II studies.
Role: PI of Subcontract at Rochester
P01 AI056356, HIV Vaccine Research and Design
Title: "HSV-1 Amplicon Vectors for HIV Vaccine Delivery"
PI: MC Keefer, M.D.
1/1/2003 – 12/31/2008
The overall goal of this Program Project is to develop an HIV vaccine strategy based on the HSV-1 amplicon vector, and to test this approach in small and large animal models. The HSV amplicon vector will be tested alone and in combination with a DNA vaccine provided by the NIAID Vaccine Research Center. The proposal includes 3 projects (immunogenicity in mice/guinea pigs; immunogenicity/protection in macaques; enhancement of amplicon technology) and 3 cores (administrative; immunologic; vector production).
P30 AI-078498, Center for AIDS Research (CFAR) program
Title: "University of Rochester Developmental Center for AIDS Research (D-CFAR)"
PI: S Dewhurst, Ph.D.
5/1/2008 – 4/30/2013
The primary mission of the University of Rochester D-CFAR is to raise the overall quality and quantity of HIV/AIDS research at the UR. This objective will be achieved by the establishment of four interconnected core facilities (Administrative Core, Developmental Core, Clinical Science Core and Basic Science Core) that synergize with the UR Clinical and Translational Science Institute to provide new opportunities for collaboration among establish investigators and those who are new to the field. Major goals are to augment the availability of biostatistical and data management services, to increase the use of mathematical modeling in HIV/AIDS research and to establish new collaborations between UR investigators and colleagues at the University of Witwatersrand and University of Cape Town in South Africa.
Role: Co-PI of D-CFAR, Director of 'Clinical Sciences Core', and Leader of 'International Collaboration Committee'.
2015 Oct 15
Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, Keefer MC, Baden LR, Swann EM, Grant S, Ahmed H, Li F, Hertz T, Self SG, Friedrich D, Frahm N, Liao HX, Montefiori DC, Tomaras GD, McElrath MJ, Hural J, Graham BS, Jin X, . "Vaccination with heterologous HIV envelope sequences and heterologous adenovirus vectors increases T cell responses to conserved regions (HVTN 083)." The Journal of infectious diseases. 2015 Oct 15; Epub 2015 Oct 15.
2015 Aug 14
Williams WB, Liao HX, Moody MA, Kepler TB, Alam SM, Gao F, Wiehe K, Trama AM, Jones K, Zhang R, Song H, Marshall DJ, Whitesides JF, Sawatzki K, Hua A, Liu P, Tay MZ, Seaton K, Shen X, Foulger A, Lloyd KE, Parks R, Pollara J, Ferrari G, Yu JS, Vandergrift N, Montefiori DC, Sobieszczyk ME, Hammer S, Karuna S, Gilbert P, Grove D, Grunenberg N, McElrath J, Mascola JR, Koup RA, Corey L, Nabel GJ, Morgan C, Churchyard G, Maenza J, Keefer M, Graham BS, Baden LR, Tomaras GD, Haynes BF. "HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies." Science. 2015 Aug 14; 349(6249):aab1253. Epub 2015 Jul 30.
Fuchs JD, Bart PA, Frahm N, Morgan C, Gilbert PB, Kochar N, DeRosa SC, Tomaras GD, Wagner TM, Baden LR, Koblin BA, Rouphael NG, Kalams SA, Keefer MC, Goepfert PA, Sobieszczyk ME, Mayer KH, Swann E, Liao HX, Haynes BF, Graham BS, McElrath MJ, . "Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals." Journal of AIDS & clinical research. 2015 May; 6(5)Epub 2015 May 23.
Kobie JJ, Zheng B, Piepenbrink MS, Hessell AJ, Haigwood NL, Keefer MC, Sanz I. "Functional and Molecular Characteristics of Novel and Conserved Cross-Clade HIV Envelope Specific Human Monoclonal Antibodies." Monoclonal antibodies in immunodiagnosis and immunotherapy. 2015 Apr; 34(2):65-72.
Huang Y, Follmann D, Nason M, Zhang L, Huang Y, Mehrotra DV, Moodie Z, Metch B, Janes H, Keefer MC, Churchyard G, Robb ML, Fast PE, Duerr A, McElrath MJ, Corey L, Mascola JR, Graham BS, Sobieszczyk ME, Kublin JG, Robertson M, Hammer SM, Gray GE, Buchbinder SP, Gilbert PB. "Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials." PloS one. 2015 10(9):e0136626. Epub 2015 Sep 02.